JSAM
REGN icon

J. Safra Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

J. Safra Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.35K Hold
15
– – ﹤0.01% 411
2026
Q1 		$11.6K Hold
15
– – ﹤0.01% 360
2025
Q4 		$11.6K Hold
15
– – ﹤0.01% 355
2025
Q3 		$8.43K Buy
+15
New +$8.48K ﹤0.01% 270
2025
Q2 		– Sell
-7
Closed -$4.44K – 392
2025
Q1 		$4.44K Buy
7
+5
+250% +$3.44K ﹤0.01% 314
2024
Q4 		$1.41K Sell
2
-1
-33% -$839 ﹤0.01% 307
2024
Q3 		$3.13K Buy
+3
New +$3.34K ﹤0.01% 263

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

J. Safra Asset Management's REGN Position: Q2 2026 in Review

J. Safra Asset Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 15 shares worth $9.35K. The position accounts for ﹤0.01% of the portfolio, ranked #411.

J. Safra Asset Management first reported a position in REGN in Q3 2024 and has held it in 7 quarters since. The position peaked at $11.6K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • J. Safra Asset Management held 15 shares of Regeneron Pharmaceuticals worth $9.35K as of Q2 2026.
  • J. Safra Asset Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #411 holding.
  • J. Safra Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • J. Safra Asset Management's Regeneron Pharmaceuticals position peaked at $11.6K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.